LLY

1,109.44

+0.48%↑

JNJ

239.41

+3.6%↑

ABBV

234.8

+2.18%↑

UNH

409.32

+0.85%↑

NVS

153.4

+3.33%↑

LLY

1,109.44

+0.48%↑

JNJ

239.41

+3.6%↑

ABBV

234.8

+2.18%↑

UNH

409.32

+0.85%↑

NVS

153.4

+3.33%↑

LLY

1,109.44

+0.48%↑

JNJ

239.41

+3.6%↑

ABBV

234.8

+2.18%↑

UNH

409.32

+0.85%↑

NVS

153.4

+3.33%↑

LLY

1,109.44

+0.48%↑

JNJ

239.41

+3.6%↑

ABBV

234.8

+2.18%↑

UNH

409.32

+0.85%↑

NVS

153.4

+3.33%↑

LLY

1,109.44

+0.48%↑

JNJ

239.41

+3.6%↑

ABBV

234.8

+2.18%↑

UNH

409.32

+0.85%↑

NVS

153.4

+3.33%↑

Search

TransMedics Group Inc

Gesloten

SectorGezondheidszorg

73.67 -2.19

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

72.59

Max

75.5

Belangrijke statistieken

By Trading Economics

Inkomsten

-98M

7.3M

Verkoop

13M

174M

K/W

Sectorgemiddelde

17.279

49.712

EPS

0.3

Winstmarge

4.206

Werknemers

898

EBITDA

-4.9M

28M

Aanbevelingen

By TipRanks

Aanbevelingen

Buy

12 Maanden Prognose

+59.25% upside

Dividenden

By Acuity

Volgende Winsten

29 jul 2026

Marktinformatie

By TradingEconomics

Marktkapitalisatie

-744M

2.6B

Vorige openingsprijs

75.86

Vorige sluitingsprijs

73.67

Nieuwssentiment

By Acuity

50%

50%

128 / 342 Rangschikking in Healthcare

TransMedics Group Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Over TransMedics Group Inc

TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its OCS includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for preservation of DBD donor hearts deemed unsuitable due to limitations of cold storage and for ex vivo reanimation, functional monitoring, and beating-heart preservation of donation-after-circulatory-death hearts; and OCS Liver for the preservation of DBD and DCD of donor livers. The company also developed national OCS program, a turnkey solution for outsourced organ retrieval; and provides OCS organ management and logistics services, including aviation and ground transportation, and other coordination activity. The company was founded in 1998 and is headquartered in Andover, Massachusetts.
help-icon Live chat